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Due  to their  vasoconstrictive  action  on the  nasal  mucosa,  ephedrine  and  pseudoephedrine  are  highly efﬁ-
cient amines  for relief  of  nasal  congestion.  As  with  any  vasoconstrictor  and  as underscored  by  the  Frenchasoconstrictor
asal congestion
Society  of Otorhinolaryngology  in  its  2011 guideline,  these  molecules  should  not be  used  in  patients
under  the  age  of 15. Furthermore,  due to unpredictable  severe  cardiovascular  and  neurological  adverse
events that  may  occur  even  at low  dose  and in the absence  of any  pre-existing  pathology,  they  should
not  be prescribed  for the  common  cold,  and  ENT  physicians  must  carefully  weigh  the  risk/beneﬁt  ratio
in  patients  with  allergic  rhinitis.  Distribution  should  be regulated  and  over-the-counter  sales  banned.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Ephedrine and pseudoephedrine are the two  oldest molecules
nown in the treatment of nasal congestion. Their vasoconstriction
ction on the nasal mucosa makes them highly effective amines
n the treatment of nasal congestion. In recent years, however, the
rench National Pharmacovigilance Commission, ﬁrst in 2008 and
hen again in 2012 [1,2], the French Otorhinolaryngology Society, in
ts 2011 Formalized Consensus Professional Guideline “Use of Vaso-
onstrictors in Rhinology” [3], and the French national Drug Safety
gency, in its July 2013 action plan [4], have all warned against their
se in rhinology. Moreover, in February 2014, the French consumer
agazine 60 Millions de Consommateurs, in a review for the general
ublic of common cold treatments on sale in France, stated that
asoconstrictors “involve a risk of stroke and severe neurological
ffects” and that they “are often too risky for use against a simple
old” [5]. Despite all of this, while in France nasal ephedrine for
asal congestion (Table 1) is a prescription-only drug, many oral
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879-7296/© 2014 Elsevier Masson SAS. All rights reserved.route symptom-relief treatments containing pseudoephedrine are
sold over the counter (Table 2).
In view of these facts, we conducted a review of the literature
to determine the beneﬁt, limitations and dangers of ephedrine and
pseudoephedrine in rhinology.
2. Ephedrine and pseudoephedrine: origins
Ephedrine is one of the 8000 natural compounds of the alka-
loid family, the etymology of which comes from the Latin alcali
(“base”), which in turn comes from the Arabic al qaliy (“soda ash”
or “burnt ash”), and the sufﬁx -oid (“like”), and which covers
all pharmacologically active alkaline heterocyclic nitrous organic
compounds [6,7]. Certain alkaloids (conventionally bearing the
sufﬁx “-ine”), such as strychnine, are notoriously deadly; many
others are used in medicine for their various therapeutic proper-
ties: analgesic (morphine, codeine, cocaine), anti-malarial (quinine,
chloroquine), anticancer (vinblastine, vincristine, vindesine), bron-
chodilatory (theophylline), vascular (adrenaline, noradrenaline,
atropine, dopamine), sialogogic (pilocarpine), anti-vertigo (scopol-
amine), or anti-allergic (histamine).
Ephedrine is named for the little bushes of the Ephedra genus,
extracts of the stem and leaves of which also contain pseu-
doephedrine and have been used for medical purposes since
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Table 1
Nasal decongestant sprays containing ephedrine on the French market in 2014.
Brand Ephedrine dose/100 mL Associated substances Dosage and maximum treatment duration
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ntiquity. In the oldest Chinese work devoted to the medicinal
irtues of animal, vegetable and mineral drugs, The Divine Farmer’s
ateria Medica (Shennong Bencao Jing), Ephedra sinica (Mahuang)
s mentioned for its stimulating and anti-asthmatic virtues [8]. In
urope, the Greek Dioscorides ﬁrst referred to the therapeutic uses
f Ephedra (Ephedra major)  and, in his Naturalis Historia, Pliny the
lder conﬁrmed these prescriptions. Some believe that this drug
ay  also be the “soma” mentioned in the Book of Hymns (Rig Veda)
f ancient India (and later recycled by Aldous Huxley as a kind of
opium of the people”, in Brave New World).
Ephedrine was ﬁrst isolated in the late 19th century, and ﬁrst
ynthesized in the 1920s in Japan as a chlorhydrate, and then
roduced and marketed by Merck [6,9]. Pseudoephedrine was syn-
hesized soon after. By virtue of their molecular structure, these
wo sympathomimetic amines stimulate the adrenergic receptor
ystem at the junction between the sympathetic nerve and smooth
uscle of the vessel walls, thus simulating the vasoconstriction
ction of norepinephrine, which is physiologically produced by the
ympathetic nerve ﬁber.
In the nasal fossae, regulation of the mucosal vascular network,
nd in particular the ﬁlling and emptying of the cavernous vein
lexuses, is fundamental to the regulation of airﬂow and hence
o the sensation of obstruction [10]. The venous plexuses, like
he arterioles accompanying them, are surrounded by adrenergic
erve ﬁbers to which they are connected by  and  adrenergic
eceptors [10]:  receptors are vasodilators, while  receptors are
asoconstrictors and are preponderant [10]. Ephedrine and pseu-
oephedrine thus exert a vasoconstrictive effect on the vessels,
hich underlies the relief they procure in nasal congestion.
. Beneﬁt of ephedrine and pseudoephedrine as nasal
econgestants
In rhinology in France, ephedrine is administered nasally and is
 prescription drug (Table 1). Pseudoephedrine, on the other hand,
hether alone or associated to various other drug classes, is taken
rally (Table 2) and is available over the counter.
Ephedrine applied to the nasal mucosa reduces nasal resistance
ore quickly and strongly than oral pseudoephedrine, but with
horter action time [10,11]. At end of treatment, there may  be a
ebound effect with increased nasal resistance and recurrence of
ongestion, for which several hypotheses have been suggested. The
011 French Society of Otorhinolaryngology guidelines [2] stress
hat rebound has been described only in experimental contexts
able 2
ver-the-counter nasal congestion treatments containing pseudoephedrine in France in 2
Brands Dose per tablet (mg) A
Humex Rhume® 60 P
Dolirhume® 30 P
DolirhumePro® 30 P
ActifedRhume® 30 P
ActifedRhume jour et nuit® 60 P
Actifed LP Rhinite Allergique® 120 A
Rhumagrip® 30 P
Rhinadvil® 30 N
Rhinureﬂex® 30 N
Nurofen Rhume® 30 N
A: paracetamol; AH: antihistamine; NSAID: non-steroidal anti-inﬂammatory drug.eptic 5 sprays/day/5 days
eptic 5 sprays/day/5 days
with healthy volunteers and might be no more than progres-
sion of the disease for which the vasoconstrictor was prescribed.
Other hypotheses involve either repeated -2 receptor stimula-
tion, inducing intense vasoconstriction with mucosal ischemia and
interstitial edema, or else -2 receptor down-regulation, induc-
ing relative dilation and a tachyphylaxic effect leading to increased
need of decongestants, or again accessory afﬁnity for  adrenergic
receptors which, when stimulated, induce secondary vasodilation
once the  effect has worn off [12,13].
Several studies in various pharmaceutical laboratories demon-
strated efﬁcacy for oral pseudoephedrine against nasal congestion
during common cold [14,15]. In 2004, the Bayer laboratories [14],
in a multicenter prospective randomized double-blind trial against
placebo including 643 patients with common cold, found reduction
of nasal congestion without side-effects 6 hours after oral intake
of pseudoephedrine (30 or 60 mg)  associated either to acetylsali-
cylic acid (1 g) or to paracetamol (500 mg  or 1 g). Likewise, in 2007,
Procter and Gamble [15], in a multicenter prospective randomized
double-blind trial against placebo including 485 patients with com-
mon  cold, found improvement in symptoms (including congestion)
3 hours after intake of syrup containing 8 mg  ephedrine associated
to 600 mg  paracetamol and a steroidal anti-inﬂammatory. Finally,
Eccles et al. [16], in a prospective randomized double-blind trial
against placebo including 238 patients with common cold, reported
efﬁcacy against nasal congestion without side-effects for 3 days’
60 mg  oral pseudoephedrine.
These results in common cold have been backed up by other
randomized double-blind studies of associated H1 antihistamines
and pseudoephedrine in allergic rhinitis [17–22]. Grosclaude et al.
[17] found that the association of an H1 antihistamine (ceti-
rizine 5 mg) and pseudoephedrine (120 mg)  for 15 days did not
improve nasal congestion more than pseudoephedrine (120 mg)
alone but did improve other symptoms. Berkowitz et al. [18,19]
found symptomatic efﬁcacy for associated H1 antihistamine (fex-
ofenadine) and pseudoephedrine (60 mg)  at 45–60 minutes after
intake, lasting 6 hours. Likewise, Chiang et al. [20] found symp-
tomatic efﬁcacy for associations of H1 antihistamines (cetirizine or
loratadine) and pseudoephedrine. In allergic rhinitis with moderate
asthma, Nathan et al. [21] found efﬁcacy compared to placebo for
4 weeks’ associated H1 antihistamine (cetirizine 5 mg) and pseu-
doephedrine (120 mg). And ﬁnally, Mucha et al. [22] found 15 days’
oral pseudoephedrine (240 mg)  to be more effective against nasal
congestion than an oral leukotriene receptor antagonist (mon-
telukast 10 mg).
014.
ssociated substances Dosage and maximum treatment duration
A 240 mg × 4 days
A 180 mg × 5 days
A 90 mg × 4 days
A 180 mg × 5 days
A + AH 180 mg × 4 days
H 240 mg × 5 days
A 180 mg × 5 days
SAID 180 mg × 5 days
SAID 180 mg × 5 days
SAID 120 mg × 5 days
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Table  3
Articles (PubMed search) published in the last 15 years reporting adverse effects for
pseudoephedrine as nasal decongestant (n: number of cases).
Authors n Side-effects
Cantu et al. [25] 4 Stroke
Browning et al. [26] 1 Angina pectoris
Manini et al. [27] 1 Myocardial infarction
Pederson et al. [28] 1 Myocardial infarction
Lopez Lois et al. [29] 1 Myoclonia and trembling
Roberge et al. [30] 1 Psychosis and ataxia
Sotullo C.A. et al. [31] 1 Psychosis
Gunn et al. [32] 1 Unexplained death
CDC [33] 3 Unexplained death
Rimsza & Newberry [34] 3 Unexplained death
Weingert et al. [35] 13 Unexplained death
Soyer et al. [36] 1 Acute urinary retention
Bektas et al. [37] 1 Supraventricular tachycardia
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IOlivier et al. [38] 58 22 cases of hypertension, 4 of stroke, 9
of  headache, 15 of vasomotor disorder
of the limbs, 8 of convulsion
. Dangers and limitations of ephedrine and
seudoephedrine
Ephedrine and pseudoephedrine belong to the amphetamine
amily. Their psychotropic effect, well-known since their
idespread use by belligerents on all sides of the Second World
ar, is one of stimulation with increased aggression and higher
atigue threshold. They are amines categorized as class A narcotics,
isted in Table I of the convention against narcotic and psychotrope
rafﬁcking since 1988. In France, in 2008 and again in 2012, the
ational Pharmacovigilance Commission [1,2] highlighted their
sychotropic action and cardiovascular side-effects.
The vasoconstriction effect these molecules exert when admin-
stered orally or directly on the nasal mucosa considerably
ncreases blood pressure and vasospasm [22–25]. This effect, which
n average lasts 5 to 6 times as long as that of adrenaline, may
nduce hypertension episodes, myocardial infarction, stroke and
arious neurological symptoms (Table 3) [10,25–38]. The various
ardiovascular adverse effects may  occur with both oral and nasal
dministration and after a single dose or prolonged (5 days) treat-
ent, without dose-effect and independently of vascular status and
ge [25–28,37]. A French study in 2003 analyzed adverse events
elated to nasal decongestant vasoconstrictors reported to regional
harmacovigilance centers by health-care professionals between
heir market launch in France and 2001 [38]. The study noted 22
pisodes of arterial hypertension, 15 of convulsion and 4 cases of
troke after oral intake of medication containing pseudoephedrine
Table 3) and 1 episode of arterial hypertension and 1 case of
troke after nasal intake of ephedrine [38]. In the USA, the Centers
or Disease Control (CDC) reported that common cold treatments
ased on nasal decongestants, H1 antihistamines, cough treatment
nd/or expectorants in under 2-year-olds had led to several hun-
red emergency hospital admissions and at least 3 deaths over
he period 2004–2005 [33]. The report conﬁrmed a case study
ublished in 2001 by Gunn et al. [32], warning physicians and
arents against uncontrolled use of these products in under 2-
ear-olds [33]. The danger was conﬁrmed by two  North American
tudies: in 2007, Wingert et al. [35], in a postmortem analysis of
amples from 13 cases of unexpected death in under-2 year-olds
aking common cold treatments in the Philadelphia region, sys-
ematically detected pseudoephedrine; likewise, in 2008, Rimsza
nd Newberry [34], in a review of the ﬁles of cases of unexpected
eath in children taking common cold treatments in 2006 in Ari-
ona, reported that the majority of victims were from socially
isadvantaged families and that postmortem toxicology, when per-
ormed, found pseudoephedrine taken for common cold in 3 cases.
n 2013, Santé Canada conﬁrmed the government’s 2002 decisiongology, Head and Neck diseases 132 (2015) 31–34 33
to limit single and maximum daily doses of pseudoephedrine as
nasal decongestant to 32 mg  and to withdraw all products with
higher doses from the Canadian market [39]. It can be seen from
Table 2 that the pseudoephedrine doses contained in the various
nasal decongestants freely available in France at the present time
are considerably higher than recommended 15 years ago by Santé
Canada [39]. It should also be borne in mind that users of over-
the-counter pseudoephedrine do not respect the recommended
doses and treatment durations and/or may associate this amine
to another class of vasoconstrictor, either over-the-counter such as
phenylephrine (Hexarhume®, Humoxal®) or on prescription such
as oxymetazoline (Aturgyl®, Déturgylone®, Pernazène®), tuamino-
heptane (Rhinoﬂuimucil®) and naphazoline (Derinox®)[3,38].
The adrenergic effect of these amines also induces hypolipi-
demia by reducing blood lipid concentrations. Combined with
their appetite suppressant effect, this led several manufacturers
to include ephedrine and Ephedra in the formulae of various diet
supplements available on the North American market in the 2000s.
However, adverse effects of the order of schizophrenia and bipolar
disorder [23,40] and the recycling of some of these amphetamines
to synthesize very easily and cheaply, methamphetamine, which is
highly addictive, led to a ban on over-the-counter sale as dietary
supplements in Canada and then, in 2006, by the US  FDA [41]. The
same danger led the French national health products safety agency
(Agence nationale de sécurité du médicament) in 2013 to reclassify
preparations containing only pseudoephedrine (Sudafed®, Humex
Rhinite Allergique®) as prescription drugs [4]; the manufacturers
subsequently withdrew both from the market in France.
5. Conclusion
The present review of the literature tends to show that their
vasoconstrictive action on the nasal mucosa makes both ephedrine
and pseudoephedrine highly effective against nasal congestion.
Like any vasoconstrictor, as stressed by the 2011 guidelines of the
French Society of Otorhinolaryngology [2], they should not be pre-
scribed for children under the age of 15 years. It further seems that
the severe adverse cardiovascular and neurological effects reported
with these amines, of unpredictable onset and potentially associ-
ated with low doses in the absence of any relevant history, should
lead ENT physicians not to resort to them to treat common cold and
to exercise the greatest rigor in assessing the cost/beneﬁt trade-off
in prescribing them for allergic rhinitis. Given these risks, distri-
bution should be regulated and over-the-counter sale should be
avoided.
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